Developer docs
API playgroundTry for free, no card

Search company profiles

PureTech Health

Full company profile

uuid0000a46

Namestring
PureTech Health
Legal namestring
PureTech Health plc
Company typeenum
Public
Founded yearint
2001
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical development, clinical-stage therapeutics, lymphatic drug delivery, deuteration chemistry, monoclonal antibody therapy
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Royalties
TypeLicensing Royalties
Description

PureTech receives royalties on approved products commercialized by partners. For Cobenfy (formerly KarXT), PureTech retains rights to 2% royalty on annual sales above $2 billion, in addition to milestone payments. Previously sold 3% royalty to Royalty Pharma on net sales up to $2 billion annually.

puretechhealth.com
2Milestone Payments
TypeLicensing Royalties
Description

PureTech receives milestone payments upon achievement of regulatory approvals and commercial sales milestones under agreements with partners like Royalty Pharma and Bristol Myers Squibb for Cobenfy.

puretechhealth.com
3Founded Entity Equity
TypeLicensing Royalties
Description

PureTech maintains significant equity positions in its Founded Entities (Celea Therapeutics, Gallop Oncology, Seaport Therapeutics) and benefits from their fundraising activities and potential future exits or IPOs.

puretechhealth.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Glyph
Description

Platform technology that enables oral bioavailability and lymphatic transport of drugs

puretechhealth.com
+4 more records
Core offering1 text field

PureTech Health is a clinical-stage biopharmaceutical company that invents and develops novel therapeutics for serious diseases through a Founded Entity model. The company advances candidates such as Cobenfy (FDA-approved for schizophrenia), deupirfenidone (idiopathic pulmonary fibrosis), and LYT-200 (myeloid malignancies), leveraging proprietary platforms including Glyph (lymphatic oral delivery), deuteration chemistry, and anti-galectin-9 antibodies. Approved products are commercialized through partnerships with large pharmaceutical companies such as Bristol Myers Squibb.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Deupirfenidone 825mg TID demonstrated 91 mL slower FVC decline vs placebo at 26 weeks (p=0.02)
+3 more records
Product overview1 text field

PureTech Health is a clinical-stage biotherapeutics company with a portfolio of therapeutic candidates at various stages of development. The company's Founded Entities include Seaport Therapeutics (advancing GlyphAllo, GlyphAgo, and Glyph2BLSD for neuropsychiatric disorders using the Glyph platform), Celea Therapeutics (advancing deupirfenidone for idiopathic pulmonary fibrosis), and Gallop Oncology (advancing LYT-200 for myeloid malignancies). PureTech also retains economic interests in Cobenfy, which was invented at PureTech and received FDA approval in September 2024 for schizophrenia.

Product and service9 records
1Seaport Therapeutics
CategoryFounded Entity
2Celea Therapeutics
CategoryFounded Entity
3Cobenfy (KarXT)
CategoryFDA Approved Product
4Gallop Oncology
CategoryFounded Entity
5Deupirfenidone (LYT-100)
CategoryClinical Candidate
6LYT-200
CategoryClinical Candidate
7GlyphAllo (SPT-300)
CategoryClinical Candidate
8GlyphAgo (SPT-320)
CategoryClinical Candidate
9Glyph2BLSD (SPT-348)
CategoryPreclinical Candidate
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Collaborative research with UC Davis for Phase 2 trial of LYT-300 (oral allopregnanolone) in treating Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Funded by up to $11.4 million from U.S. Department of Defense.

Strategic tierCoreTypeTechnology or Integration
Description

PureTech acquired deupirfenidone (LYT-100) from Auspex Pharmaceuticals (now wholly owned subsidiary of Teva Pharmaceuticals) in July 2019. Auspex pioneered deuteration technology which achieved first-ever FDA approval for a deuterated drug with Austedo.

3New York University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partnership for LYT-200 (anti-galectin-9 monoclonal antibody). PureTech invented LYT-200 in conjunction with partners at NYU, leveraging early access to foundational research on galectin-9 before its publication in Nature Medicine.

puretechhealth.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial and supply agreement to evaluate LYT-200 and tislelizumab in patients with difficult-to-treat solid tumors.

5Monash University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensed the Glyph platform technology from Monash University and continued to refine it before housing it in Seaport Therapeutics. Collaboration includes ongoing research including Phase 2b BUOY-1 trial for GlyphAllo.

puretechhealth.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Roivant Sciences operates a virtually identical Vant/Founded Entity model, creating subsidiary companies to develop specific therapeutic candidates. Both companies specialize in taking validated pharmacology and applying targeted innovation to address unmet medical needs across multiple therapeutic areas.

TypeDirect peer
Description

Royalty Pharma is the largest dedicated pharmaceutical royalty buyer. PureTech's business model directly involves acquiring and monetizing royalty streams (e.g., Cobenfy royalties), making Royalty Pharma a direct comparable in how biotech royalty assets are valued and traded.

TypeDirect peer
Description

BridgeBio operates a multi-asset rare disease biotech model with multiple subsidiaries advancing parallel programs. Like PureTech, BridgeBio maintains a portfolio of clinical-stage assets across diverse therapeutic areas and pursues capital-efficient development through entity-level financings.

TypeDirect peer
Description

Axsome is a CNS specialty pharmaceutical company with FDA-approved therapies in depression and migraine. Like PureTech's Cobenfy (first new schizophrenia mechanism in 50 years), Axsome developed Auvelity as a novel mechanism in depression, representing comparable CNS specialty pharma innovation.

TypeDirect peer
Description

Sage Therapeutics focused on neuropsychiatric therapies (depression, epilepsy) and was acquired by Biogen. PureTech's Seaport Therapeutics has overlapping neuropsychiatric focus on MDD and GAD, making Sage a directly comparable specialty CNS biotech.

TypeDirect peer
Description

FibroGen developed pamrevlumab and roxadustat, with significant focus on idiopathic pulmonary fibrosis (IPF). PureTech's Celea Therapeutics with deupirfenidone targets the same IPF market, making FibroGen a direct comparator in pulmonary fibrosis drug development.

TypeDirect peer
Description

Karuna Therapeutics was PureTech's Founded Entity that developed Cobenfy (KarXT), which was acquired by Bristol Myers Squibb for $14 billion in March 2024. It serves as the historical template for PureTech's Founded Entity model in neuropsychiatric drug development.

TypeDirect peer
Description

Galapagos is a specialty biotech focused on immunology and fibrosis with a similar multi-asset clinical pipeline. The company's work in fibrotic diseases (IPF) directly parallels Celea Therapeutics' deupirfenidone program, and Galapagos operates a comparable specialty pharma innovation model.

TypeBroad incumbent
Description

BioMarin is a larger rare disease specialty pharmaceutical company with multiple Orphan Drug Designations and FDA-approved therapies. While broader in scope, BioMarin shares PureTech's strategy of targeting rare/specialty indications with multiple program-specific development approaches.

TypeBroad incumbent
Description

Vertex is an established biopharmaceutical innovator with a strong track record of taking validated mechanisms and developing transformative therapies. PureTech's 6x industry-average clinical success rate and focus on serious diseases with high unmet need parallels Vertex's specialty innovation approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment28 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PureTech Health

Clinical-Stage Biopharmaceuticalspuretechhealth.com

PureTech Health firmographics

Firmographics
Name
PureTech Health
Legal name
PureTech Health plc
Website
https://puretechhealth.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

PureTech Health industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Biopharmaceutical development
  • Clinical-stage therapeutics
  • Lymphatic drug delivery
  • Deuteration chemistry
  • Monoclonal antibody therapy

Where PureTech Health is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PureTech Health business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Licensing Royalties: PureTech receives royalties on approved products commercialized by partners. For Cobenfy (formerly KarXT), PureTech retains rights to 2% royalty on annual sales above $2 billion, in addition to milestone payments. Previously sold 3% royalty to Royalty Pharma on net sales up to $2 billion annually.
  2. Milestone Payments: PureTech receives milestone payments upon achievement of regulatory approvals and commercial sales milestones under agreements with partners like Royalty Pharma and Bristol Myers Squibb for Cobenfy.
  3. Founded Entity Equity: PureTech maintains significant equity positions in its Founded Entities (Celea Therapeutics, Gallop Oncology, Seaport Therapeutics) and benefits from their fundraising activities and potential future exits or IPOs.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

PureTech Health product offering

Product offering

Core offering

PureTech Health is a clinical-stage biopharmaceutical company that invents and develops novel therapeutics for serious diseases through a Founded Entity model. The company advances candidates such as Cobenfy (FDA-approved for schizophrenia), deupirfenidone (idiopathic pulmonary fibrosis), and LYT-200 (myeloid malignancies), leveraging proprietary platforms including Glyph (lymphatic oral delivery), deuteration chemistry, and anti-galectin-9 antibodies. Approved products are commercialized through partnerships with large pharmaceutical companies such as Bristol Myers Squibb.

Product overview

PureTech Health is a clinical-stage biotherapeutics company with a portfolio of therapeutic candidates at various stages of development. The company's Founded Entities include Seaport Therapeutics (advancing GlyphAllo, GlyphAgo, and Glyph2BLSD for neuropsychiatric disorders using the Glyph platform), Celea Therapeutics (advancing deupirfenidone for idiopathic pulmonary fibrosis), and Gallop Oncology (advancing LYT-200 for myeloid malignancies). PureTech also retains economic interests in Cobenfy, which was invented at PureTech and received FDA approval in September 2024 for schizophrenia.

Differentiator

Problem solved

Functional benefit

Brands

  • Glyph: Platform technology that enables oral bioavailability and lymphatic transport of drugs
  • GlyphAllo (SPT-300)
  • GlyphAgo (SPT-320)
  • Celea Therapeutics
  • Gallop Oncology

Products and services

  • Seaport Therapeutics
  • Celea Therapeutics
  • Cobenfy (KarXT)
  • Gallop Oncology
  • Deupirfenidone (LYT-100)
  • LYT-200
  • GlyphAllo (SPT-300)
  • GlyphAgo (SPT-320)
  • Glyph2BLSD (SPT-348)

Quantifiable outcome

  • Deupirfenidone 825mg TID demonstrated 91 mL slower FVC decline vs placebo at 26 weeks (p=0.02)
  • +3 more outcomes

Companies that use PureTech Health

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

PureTech Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

PureTech Health partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • UC DaviscoreStrategic or Co-development Partner · 1 August 2023Collaborative research with UC Davis for Phase 2 trial of LYT-300 (oral allopregnanolone) in treating Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Funded by up to $11.4 million from U.S. Department of Defense.
  • Auspex Pharmaceuticals (Teva)coreTechnology or IntegrationPureTech acquired deupirfenidone (LYT-100) from Auspex Pharmaceuticals (now wholly owned subsidiary of Teva Pharmaceuticals) in July 2019. Auspex pioneered deuteration technology which achieved first-ever FDA approval for a deuterated drug with Austedo.
  • New York UniversitycoreStrategic or Co-development PartnerCo-development partnership for LYT-200 (anti-galectin-9 monoclonal antibody). PureTech invented LYT-200 in conjunction with partners at NYU, leveraging early access to foundational research on galectin-9 before its publication in Nature Medicine.
  • BeiGeneminorStrategic or Co-development PartnerClinical trial and supply agreement to evaluate LYT-200 and tislelizumab in patients with difficult-to-treat solid tumors.
  • Monash UniversitycoreStrategic or Co-development PartnerLicensed the Glyph platform technology from Monash University and continued to refine it before housing it in Seaport Therapeutics. Collaboration includes ongoing research including Phase 2b BUOY-1 trial for GlyphAllo.

Scale indicators14 records

Recent moves10 records

Expansion highlights5 records

PureTech Health competitors and assessment

Company assessment

Direct peers

  • Roivant Sciences: Roivant Sciences operates a virtually identical Vant/Founded Entity model, creating subsidiary companies to develop specific therapeutic candidates. Both companies specialize in taking validated pharmacology and applying targeted innovation to address unmet medical needs across multiple therapeutic areas.
  • Royalty Pharma: Royalty Pharma is the largest dedicated pharmaceutical royalty buyer. PureTech's business model directly involves acquiring and monetizing royalty streams (e.g., Cobenfy royalties), making Royalty Pharma a direct comparable in how biotech royalty assets are valued and traded.
  • BridgeBio Pharma: BridgeBio operates a multi-asset rare disease biotech model with multiple subsidiaries advancing parallel programs. Like PureTech, BridgeBio maintains a portfolio of clinical-stage assets across diverse therapeutic areas and pursues capital-efficient development through entity-level financings.
  • Axsome Therapeutics: Axsome is a CNS specialty pharmaceutical company with FDA-approved therapies in depression and migraine. Like PureTech's Cobenfy (first new schizophrenia mechanism in 50 years), Axsome developed Auvelity as a novel mechanism in depression, representing comparable CNS specialty pharma innovation.
  • Sage Therapeutics: Sage Therapeutics focused on neuropsychiatric therapies (depression, epilepsy) and was acquired by Biogen. PureTech's Seaport Therapeutics has overlapping neuropsychiatric focus on MDD and GAD, making Sage a directly comparable specialty CNS biotech.
  • FibroGen: FibroGen developed pamrevlumab and roxadustat, with significant focus on idiopathic pulmonary fibrosis (IPF). PureTech's Celea Therapeutics with deupirfenidone targets the same IPF market, making FibroGen a direct comparator in pulmonary fibrosis drug development.
  • Karuna Therapeutics: Karuna Therapeutics was PureTech's Founded Entity that developed Cobenfy (KarXT), which was acquired by Bristol Myers Squibb for $14 billion in March 2024. It serves as the historical template for PureTech's Founded Entity model in neuropsychiatric drug development.
  • Galapagos NV: Galapagos is a specialty biotech focused on immunology and fibrosis with a similar multi-asset clinical pipeline. The company's work in fibrotic diseases (IPF) directly parallels Celea Therapeutics' deupirfenidone program, and Galapagos operates a comparable specialty pharma innovation model.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is a larger rare disease specialty pharmaceutical company with multiple Orphan Drug Designations and FDA-approved therapies. While broader in scope, BioMarin shares PureTech's strategy of targeting rare/specialty indications with multiple program-specific development approaches.
  • Vertex Pharmaceuticals: Vertex is an established biopharmaceutical innovator with a strong track record of taking validated mechanisms and developing transformative therapies. PureTech's 6x industry-average clinical success rate and focus on serious diseases with high unmet need parallels Vertex's specialty innovation approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PureTech Health social profiles

Digital presence

PureTech Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PureTech Health leadership team

Management profile

Number of profiles

Profiles8 records

PureTech Health subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

PureTech Health funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PureTech Health M&A and investment

M&A and investment

M&A

Investments28 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PureTech Health

What does PureTech Health do?

PureTech Health is a clinical-stage biopharmaceutical company that invents and develops novel therapeutics for serious diseases through a Founded Entity model. The company advances candidates such as Cobenfy (FDA-approved for schizophrenia), deupirfenidone (idiopathic pulmonary fibrosis), and LYT-200 (myeloid malignancies), leveraging proprietary platforms including Glyph (lymphatic oral delivery), deuteration chemistry, and anti-galectin-9 antibodies. Approved products are commercialized through partnerships with large pharmaceutical companies such as Bristol Myers Squibb.

Is PureTech Health a public or private company?

PureTech Health is a public company. It is classified as public and is currently operating.

When was PureTech Health founded?

PureTech Health was founded in 2001. It employs 51 to 100 people.

Where is PureTech Health based?

PureTech Health is headquartered in Boston, United States, in the North America region.

How does PureTech Health make money?

Three revenue lines are on record. Licensing Royalties are the primary driver. The others are milestone Payments and founded Entity Equity.

Who are PureTech Health's main competitors?

Direct peers on record are Roivant Sciences, Royalty Pharma, BridgeBio Pharma, Axsome Therapeutics, Sage Therapeutics, FibroGen, Karuna Therapeutics and Galapagos NV. Broad incumbents are BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Does PureTech Health have an API?

No public API is recorded for PureTech Health.

What industry is PureTech Health in?

PureTech Health's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewREG - PureTech Health PLC - Holding(s) in CompanyBriarwood Chase Management LLC notified the UK regulator of a major holding in PureTech Health PLC, crossing the 10% threshold on 11 November 2026. The company now holds 11.3958% of voting rights, up from 10.1441% previously.TradingViewREG - PureTech Health PLC - Holding(s) in CompanyLansdowne Partners (UK) LLP notified the UK regulator of crossing the 5% voting rights threshold in PureTech Health PLC on 29-Oct-2026. The firm holds 12,178,974 shares, representing 4.967367% of voting rights.Business Wire BlogPureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity CategoryPureTech Health won the 2026 Prix Galien USA Award for Incubators, Accelerators and Equity, presented at the ceremony on October 29, 2026. The company's hub-and-spoke model has delivered an 80% clinical trial success rate and three FDA-approved therapeutics, with Founded Entities attracting over $4 billion in third-party financing since 2018.InvestegatePRTC's Gallop Presents Ph1b LYT-200 Data at ESMOPureTech Health presented Phase 1b data for LYT-200 at ESMO 2026, showing a 36.4% complete response rate in R/R HR-MDS patients treated with LYT-200 plus an HMA. The trial of 101 patients had no dose-limiting toxicities, and Gallop plans a Phase 2 STRIDE-MDS trial after FDA Fast Track designation.TradingViewRCS - PureTech Health PLC - PRTC's Gallop Presents Ph1b LYT-200 Data at ESMOPureTech Health presented Phase 1b data for LYT-200 at ESMO 2026, showing a 36.4% complete response rate in R/R HR-MDS patients treated with LYT-200 plus an HMA. The trial of 101 patients had no dose-limiting toxicities, and Gallop plans a Phase 2 STRIDE-MDS trial after FDA Fast Track designation.Business & FinancialIdiopathic Pulmonary Fibrosis Pipeline 2026: Who Is Leading The Race? Top Companies And Emerging Therapies To Watch By Delveinsight Boehringer Ingelheim, Puretech, Guangzhou JOYO PharmaDelveInsight's 2026 pipeline report profiles IPF therapies from Boehringer Ingelheim, PureTech, and others. Key updates include Oorja Bio's Phase II ORBIT-IPF trial launch, Bristol Myers Squibb's positive topline from the ALOFT-IPF trial, and United Therapeutics' FDA-accepted sNDA for Tyvaso in IPF.Defense WorldPureTech Health (LON:PRTC) Stock Breaks Below 50 Day Moving Average – Time to Sell?PureTech Health shares fell below their 50-day moving average on Monday, trading at GBX 115.40 against a 50-day average of GBX 117.59. Analysts rate the stock a Buy with a consensus target of GBX 508, and insiders purchased 469,720 shares in the last quarter.TradingViewRCS - PureTech Health PLC - PRTC's Gallop to Present Ph1b LYT-200 Data at ESMOPureTech Health will present Phase 1b results for LYT-200 at ESMO 2026, highlighting clinical activity and favorable safety in relapsed/refractory high-risk MDS and AML. The data support advancing LYT-200 into a Phase 2 STRIDE-MDS trial after FDA End-of-Phase 1 and Fast Track designation.American Banking and Market NewsPureTech Health plc (OTCMKTS:PTCHF) Stock Short Interest Report for SeptemberPureTech Health's short interest fell 73.7% to 15,775 shares as of September 30, down from 59,901 on September 15. The stock opened at $1.51, with a 50-day moving average of $1.57 and a 200-day average of $1.64.American Banking and Market NewsPureTech Health (LON:PRTC) Stock Breaks Below Fifty Day Moving Average – Here’s WhyPureTech Health shares fell below their 50-day moving average on Friday, trading at GBX 111. Peel Hunt reaffirmed a buy rating with a GBX 508 target, and insiders purchased 469,720 shares over the past 90 days.